

### REMARKS

By the foregoing amendments, the non-elected claims have been canceled without prejudice to the right to file a continuing application directed thereto.

For convenience, claim 30 has been canceled and presented new as claim 33 which is identical to prior claim 30 except that the "capable of" language has been deleted, a period has been added at the end and reference to compound 23 has been deleted. It is respectfully submitted that this claim is free of the objections and rejections set forth in the Office Action.

A series of claims to individual species within claim 33 has been presented for consideration.

All of the compounds of claim 33 are capable of reducing the virulence in Gram-negative bacteria having a type III secretion (TTS) system. Accordingly, a claim to the use of these compounds for that purpose has been presented as new claim 39, and a series of species claims have also been presented. The fact that the compounds have this property and can be so used is clearly surprising and unexpected. The fact that the same compounds are present in both main claims also satisfies the unity of invention requirement for a common special technical feature.

Claim 41 is dependent on claim 39 and specifies that the compound is selected is a compound recited in claim 39 in which the groups directly bonded to the carbonyl group and nitrogen have certain characteristics and is thus generic to compounds 24 through 29, 31 and 32.

Application No. 10/526,461  
Amendment dated January 19, 2007  
Reply to Office Action of November 13, 2006

Docket No.: C2432.0061

In view of the above amendment, applicant believes the pending application is in condition for allowance.

Dated: January 19, 2007

Respectfully submitted,

By Edward A. Meilman

Edward A. Meilman

Registration No.: 24,735

DICKSTEIN SHAPIRO LLP

1177 Avenue of the Americas

41st Floor

New York, New York 10036-2714

(212) 277-6500

Attorney for Applicant